Patrick A. Zweidler-McKay, M.D., Ph.D.

Patrick Zweidler-McKay M.D. Ph.D. serves as Chief Medical Officer of Sidewinder Therapeutics. With over 23 years of experience in oncology clinical care and research, Dr. Zweidler-McKay is a leader in oncology clinical development strategy, including global regulatory engagement. Prior to Sidewinder, he was Executive Director at ImmunoGen and Global Development Lead at AbbVie. He has focused exclusively on ADC programs, leading 12 ADC development candidates, including five clinical stage programs, one of which is approved (Elahere) and a second to be reviewed by FDA in 2025. At ImmunoGen, he worked closely with the C-suite, leading BD interactions for both outgoing and incoming programs. Prior to ImmunoGen, Dr. Zweidler-McKay served as Deputy Department Chair of Pediatric Oncology at MD Anderson Center, where he led the Leukemia & Lymphoma Section, and ran a two R01-funded research laboratory. In addition, Dr. Zweidler-McKay chaired international clinical trials, served as a full member of the Clinical Oncology Study Section, Pediatric Editor for CANCER, and an expert reviewer for the National Academy of Sciences, among other achievements. He has published over 76 research papers and book chapters in oncology and has >10,000 citations.